

Modern Slavery Act Statement

Intercept Pharma Europe Ltd. (“Intercept”) supports the UK’s Modern Slavery Act 2015.

This statement has been prepared in response to Section 54 of the Modern Slavery Act 2015 and outlines Intercept’s policies and efforts to mitigate the risks of slavery and human trafficking throughout our business and supply chain. It covers Intercept’s last financial year.

Intercept is committed to sound corporate governance principles, practices, and policies. To learn more about our corporate compliance policies, please visit: <https://www.interceptpharma.com/corporate-compliance/>

Managing modern slavery risks

We recognize our responsibility to identify, mitigate and address potential and actual human rights risks that are directly linked to our business activities around the world. While the potential for modern slavery and human trafficking is relatively lower in the highly regulated biopharmaceutical industry than in many other industries, we recognize that this responsibility also extends to our business relationships.

We continue to take steps to mitigate the risks associated with slavery and human trafficking in our business and supply chain. These include the below activities:

Verification and risk assessment: As part of our procurement vendor diligence process, all high risk suppliers are vetted by our screening process which is intended to flag identified modern slavery and human trafficking risks.

We have implemented a centralized Vendor Management and Onboarding process and technology in order to increase Vendor information efficiency with a centralized information base, identity and manage vendor risk as well as increase monitoring of vendor performance. This process covers multiple lines of vendor due diligence including but not limited to Anti-Slavery, Anti-Corruption Anti-Bribery, Compliance, Quality Assurance, Data Privacy and Information Technology.

Employee training: Our Global Code of Business Conduct outlines expectations for employees to conduct business with integrity. New and existing employees are periodically required to review the Code and complete required training. We also provide a compliance hotline where employees can report any matters of concern from a compliance or policy perspective and report anonymously if they wish.

On an ongoing basis, we have put in place and are updating an annual compliance process with our distributors which, amongst other matters, reinforces our joint commitment to conducting business ethically.

We will report on further progress in our next statement.

Intercept Pharma Europe Ltd.

November 2019